Vutrisiran Reduces All-Cause Mortality, Cardiovascular Mortality, And Cardiovascular Events In Patients With Transthyretin Amyloid Cardiomyopathy: Analysis From The HELIOS-B Trial

Journal of Cardiac Failure 2026

View at publisher
Authors: Ronald M. Witteles, Pablo García‐Pavía, Thibaud Damy, Martha A. Grogan, Farooq H. Sheikh, Caroline Morbach, Shaun D. Bender, Jason Exter, Satish A. Eraly, M Fontana
DOI: 10.1016/j.cardfail.2025.11.043
Cited by: 0

Fields of Study & Subjects

Amyloidosis: Diagnosis Treatment Outcomes Heart Failure Treatment and Management Alzheimer's disease research and treatments

Publication details

Journal / source
Journal of Cardiac Failure
Volume
32
Issue
1
Pages
189–189
Publication date
1 January 2026
Language
EN